Business
NurExone Announces Sponsorship and Participation in Gordon Research's 2022 Extracellular Vesicles Conference in Maine, U.S.
Calgary, Alberta--(Newsfile Corp. - July 25, 2022) - NurExone Biologic Inc. (TSXV: NRX) ("NurE...
About this update from Nurexone Biologic Inc
[{"type":"text","content":"NurExone Announces Sponsorship and Participation in Gordon Research's 2022 Extracellular Vesicles Conference in Maine, U.S.Calgary, Alberta--(Newsfile Corp. - July 25, 2022) - NurExone Biologic Inc. (TSXV: NRX) (\"NurExone\" or the \"Company\"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal injuries and other Central Nervous System (\"CNS\") indications, is pleased to announce that it will showcase a poster presentation at the prestigious \"Understanding Extracellular Vesicle Biogenesis and Composition for Detection and Treatment of Diseases\" conference, hosted by Gordon Research Conference's (\"GRC\") in Newry, Maine, U.S.The goal of this conference is to dive into the rapidly growing space of extracellular vesicles and extracellular RNA while bringing in a variety of clinical investigators who are experts in the field. The conference, which commenced on July 24, 2022 and will end on July 29, 2022, will explore the impact that extracellular vesicles (EVs) have on maintaining health, tissue regeneration and more.NurExone is one of the sponsors of the conference and will set up an in-depth poster presentation detailing its revolutionary ExoPTEN technology and the role it plays in spinal cord regeneration. The presentation covers the science behind exosomes, offers several proofs-of-concept, and demonstrates how the intranasal treatment leads to locomotor, sensory, and bladder recovery.\"GRC offers a distinguished international forum for the latest scientific developments and we are excited to be included in the 2022 Extracellular Vesicles Conference to showcase our innovative exosome-based technology,\" said Dr. Lior Shaltiel, CEO of NurExone. \"The conference will provide us with the opportunity to raise awareness about the promise of nanocarriers for drug delivery and targeted therapy, in front of an international audience consisting of renowned scientists and experts in the field of extracellular vesicles.\"The conference is being held in Maine at the Grand Summit Hotel at Sunday River.About NurExoneNurExone Biologic Inc. is a TSXV listed pharmaceutical company that is developing a platform for biologically-guided ExoTherapy to be delivered, non-invasively, to patients who suffered traumatic spinal cord injuries. The Company's ExoTherapy will use proprietary exos...